- Home
- FDMT vs TECX Comparison
FDMT vs TECX Comparison
Compare FDMT & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FDMT | TECX |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 431.4M | 366.8M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FDMT | TECX |
|---|---|---|
| Price | $7.98 | $20.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $34.29 | ★ $80.40 |
| AVG Volume (30 Days) | ★ 747.3K | 223.4K |
| Earning Date | 02-27-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $120,000.00 | N/A |
| Revenue This Year | $21,227.03 | N/A |
| Revenue Next Year | $161.87 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 605.88 | N/A |
| 52 Week Low | $2.24 | $13.70 |
| 52 Week High | $12.34 | $61.07 |
Technical Indicators
Market Signals| Indicator | FDMT | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 46.64 | 52.04 |
| Support Level | $7.30 | $17.77 |
| Resistance Level | $7.80 | $19.64 |
| Average True Range (ATR) | 0.53 | 1.37 |
| MACD | 0.14 | -0.15 |
| Stochastic Oscillator | 55.27 | 57.36 |
Price Performance
Historical ComparisonAbout FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
About TECX Tectonic Therapeutic Inc.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.